Synergy Pharmaceuticals Inc. expects top-line data from its first phase III trial of Plecanatide for chronic idiopathic constipation in the second quarter of 2015, and top line data from the second phase III trial of Plecanatide for chronic idiopathic constipation in the third quarter of this year.